Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR) Short Interest Down 94.5% in July

Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR) was the recipient of a significant drop in short interest in the month of July. As of July 15th, there was short interest totaling 3,571 shares, a drop of 94.5% from the June 30th total of 65,392 shares. Approximately 0.4% of the shares of the company are short sold. Based on an average daily volume of 99,268 shares, the days-to-cover ratio is currently 0.0 days.

Cuprina Holdings (Cayman) Price Performance

Shares of NASDAQ CUPR traded up $0.03 during mid-day trading on Friday, hitting $3.34. The company had a trading volume of 12,799 shares, compared to its average volume of 1,379,201. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.35 and a current ratio of 2.35. Cuprina Holdings has a 1 year low of $1.76 and a 1 year high of $76.00. The business’s 50-day simple moving average is $3.91.

Cuprina Holdings (Cayman) (NASDAQ:CUPR) last issued its quarterly earnings data on Monday, April 27th. The company reported ($0.40) earnings per share (EPS) for the quarter. The company had revenue of $0.01 million during the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Cuprina Holdings (Cayman) from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

Cuprina Holdings (Cayman) Company Profile

We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. We believe we will be able to build upon and leverage such expertise to develop innovative cosmeceutical products in the future.